17,000 Australian's will be diagnosed with bowel cancer this year. Over 4,000 will die from their disease. We need to change this.
Our research is using molecular analyses to improve prevention, provide earlier diagnostic and better prognostic biomarkers and optimize treatments.
Some recent selected publications
The Molloy lab uses mass spectrometry for proteomic and metabolite analyses and genomics to study cancer and other diseases.
Our oncology publications are in the following cancers: colorectal, lung, thyroid, melanoma, mesothelioma, prostate, pancreatic.
We also use mass spectrometry to study other diseases including neurodegenerative diseases (MND, Alzheimer's) and diabetes.
The Molloy lab has also developed new technology approaches for proteomics including bioinformatic solutions
Mark P Molloy
Mark is Head of the Bowel Cancer and Biomarker laboratory at the Kolling Institute, The University of Sydney, and the inaugural Lawrence Penn chair of Bowel Cancer Research. He is a translational biochemist and international expert in proteomic analysis with o
Official launch event for the Lawrence Penn chair of Bowel Cancer Research at The University of Sydney.